COTA, Inc. announces Ritu Bahal has joined the company to serve as Chief Financial Officer
As CFO, Ritu will oversee all aspects of COTA’s financial strategy as it enters the next phase of growth. She will support COTA’s overall mission of bringing clarity to cancer care by devising and implementing sound financial strategies to maximize revenue growth and operational efficiencies, increasing financial transparency and engaging with investors.
Growing Our Team During the Pandemic
Thanks to the pandemic, remote work is more collaborative, but hiring and onboarding new employees has its share of challenges. Thankfully we were able to pivot and COTA is proud of the process we’re using to recruit new employees.
Study: Cancer Patients and Their Families Frustrated with Slow Pace of Drug and Treatment Innovation
COTA announced findings from a study that found 66 percent of cancer patients and their immediate families surveyed think that the speed of clinical trials aimed at driving much-needed innovations in cancer treatments and therapies remains far too slow. The study, which surveyed 1,110 Americans who’ve either had cancer or who’ve had someone in their immediate family with cancer, also found that the recent rapid development of multiple COVID-19 vaccines heightened this belief.
COTA to Accelerate Life Sciences Impact With Addition of Christine Kawiecki from IBM Watson Health
With more than 25 years of healthcare experience, Christine Kawiecki joins the COTA, Inc. team to support business growth as life sciences companies are increasingly turning to real-world data to accelerate drug development in a post-pandemic world.
Connecting Providers, Patients, and Life Sciences to Drive Scientific Breakthroughs
Despite having shared goals like improving patient outcomes with new and life-saving treatments, providers and life science companies operate as separate entities, making it difficult to bring blockbuster drugs out of the lab and into the real world. Companies like COTA help solve this problem.
The Questions You Should Be Asking When Evaluating Real-World Data
With a thriving data marketplace and rising enthusiasm, it’s easy to get excited by promises and possibilities of what real-world data (RWD) has to offer, but not all RWD is created equal and it’s important to remember that quality is more important than quantity
Data Standardizations Support Collaboration Across RWD Stakeholders
Most real-world data (RWD) sets aren’t usable directly from the source. Adopting established standards to curate reliable, sharable insights is key for unleashing the potential of rich data assets. Read how COTA is working with HemOnc.org, OMOP, and Health Language to create the deepest, longitudinal, highest quality RWD to drive cancer research.
COTA and MedStar Health Partner To Drive Scientific Research and Expedite Delivery of Innovative Cancer Treatments
MedStar Health will leverage COTA’s real-world data expertise to deliver more precise care for cancer patients
Making a Difference for Cancer Patients with Hybrid and External Control Arms in Clinical Trials
While the traditional approach of studying control and intervention arms concurrently is an effective way to bring new treatment options to patients, the growing availability of high-quality real-world data (RWD) is changing the way we can accelerate results.
Abstracts Accepted for Publication at ASCO 2021
Three abstracts submitted by COTA and various collaborators have been accepted for publication at this year’s meeting. These abstracts demonstrate COTA’s commitment to working with all stakeholders – across healthcare – to bring clarity to cancer care with real-world data.
